Martin David Harp

At the Envision Summit 2025 in San Juan, Puerto Rico, Ashley Wallace Tucker, OD, FAAO, FSLS, gave insight into advancements in keratoconus management and the importance of early detection as well as tips and advice on fitting scleral contact lens

At the Envision Summit 2025 in San Juan, Puerto Rico, Lana Rifkin, MD, gave clinicians advice on how, and when it may be most appropriate to use the new G2211 code.

At the Envision Summit 2025 in San Juan, Puerto Rico, Arjan Hura, MD, talked about EVO ICL surgery, its benefits, and how every ophthalmologist has the ability and training to conduct the surgery even if they aren't aware.

At the Envision Summit 2025 in San Juan, Puerto Rico, Nita Valikodath, MD, MS, gave insight into a challenging case of a 14-year-old boy who had trauma-related retinal detachment in his right eye, where a further macula-on retinal detachment with retinal dialysis was found in the left.

At the Envision Summit 2025 in San Juan, Puerto Rico, Deepak Sambhara, MD, gave insight into the 96-week post hoc fluid outcomes analysis of patients who participated in the phase 3 clinical trial PULSAR.

At the Envision Summit 2025 in San Juan, Puerto Rico, Carol Karp, MD, discussed new research presented by her fellows at the meeting on AI for the diagnosis of ocular surface tumors as well as a new "tear biopsy" for the detection of cancer.

At the Envision Summit 2025 in San Juan, Puerto Rico, Brittany Simmons, MD, discussed periorbital injuries and how they can affect the soft tissue and bones around the eye and gives insight into how clinicians should best go about treating it.

At the Envision Summit 2025 in San Juan, Puerto Rico, Jessica Steen, OD, FAAO talked with glaucoma surgeons on the importance of comanaging patients throughout their lifetime.

Laxmi Devisetty, MD, and Eva Kim, MD, look ahead at upcoming sessions focusing on geographic atrophy and refractive and cataract surgery at the Envision Summit 2025.

According to the company, the suffix “-mod” in urcosimod denotes its classification as a modulator of key inflammatory and neuropathic pathways.

The 2 phase II trials, Osprey and Apteryx successfully met all primary and secondary endpoints.

Results were published from the phase 3 QUASAR trial and the extension study of the phase 3 PULSAR trial.

PRISM evaluates 4D-150, a potential backbone therapy designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) from the retina with a single, safe, intravitreal injection.

Susvimo 100 mg/mL for intravitreal use via ocular implant is a refillable implant surgically inserted into the eye during a one-time, outpatient procedure, continuously delivering a customized formulation of ranibizumab over time.

Results from the study assisted Notal Vision in receiving De Novo authorization from the US FDA for the SCANLY Home OCT in 2024.

Laru-zova is a gene therapy currently being investigated for the treatment of patients with X-linked retinitis pigmentosa.

The device recently received 510(k) clearance from the US Food and Drug Administration.

Zhaoke Ophthalmology Limited is responsible for developing and obtaining regulatory approval for NVK-002 in Greater China, South Korea, and the Southeast Asian territories.

The Sentinel Camera aims to address critical gaps in retinal disease screening by offering a portable device that captures high-quality images that require no dilation of the eye.

The approval of Syfovre makes it the first and only approved treatment for GA in Australia.

The meetings support the company’s submission for its bioengineered corneal implants to eliminate corneal blindness.

ARCATUS or ARVN001, in Greater China, South Korea, Australia, New Zealand, India and the ASEAN Countries is formally known as XIPERE in the United States and was developed by Clearside Biomedical.

Topline data results are expected in February 2025.

The iDose platform is designed to address ubiquitous patient non-adherence and chronic side effects associated with topical medications by providing 24/7 release of medication.

The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal injection in 3 cohorts.

The trial evaluated ONS-5010 in wet age-related macular degeneration patients, and the company plans to resubmit a Biologics License Application in the first quarter of 2025.

The launch follows a CE Mark received late last year.

Whitecap is currently developing 2 therapies for potential use in glaucoma and geographic atrophy.

The Loong Crystal PR IOL is designed for the treatment of myopia in adults ranging from -3.25D to -18.00D.